{"id":"eltoprazine-hcl","_chembl":{"chemblId":"CHEMBL3187065","moleculeType":"Small molecule","molecularWeight":"256.73"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"5-HT1A and 5-HT1B receptors","explanation":"Eltoprazine functions as a serotonin receptor agonist with selectivity for 5-HT1A and 5-HT1B receptor subtypes. By modulating serotonergic neurotransmission, it may help regulate motor control and behavioral symptoms in neurological disorders.","oneSentence":"Eltoprazine modulates serotonin receptors in the brain, particularly acting as an agonist at 5-HT1A and 5-HT1B receptors."},"_scrapedAt":"2026-03-28T02:37:03.788Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123846,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"Pimavanserin","brand":"Nuplazid","company":"Acadia Pharmaceuticals","rationale":"Serotonin modulator for Parkinson's disease-related symptoms"},{"name":"Amantadine","brand":"Gocovri","company":"Adamas Pharmaceuticals","rationale":"Approved treatment for levodopa-induced dyskinesia in Parkinson's"}],"description":"Eltoprazine HCl is a serotonin receptor modulator in Phase 2 development by Amarantus BioScience Holdings for neurological and psychiatric conditions. The compound acts on serotonin pathways in the central nervous system and has been investigated for disorders including Parkinson's disease levodopa-induced dyskinesia and aggression.","indications":{"approved":[{"status":"investigational","condition":"Levodopa-induced dyskinesia in Parkinson's disease","patientPopulation":"Adult patients with Parkinson's disease experiencing dyskinesia"},{"status":"investigational","condition":"Aggression and agitation","patientPopulation":"Adult patients with neurological or psychiatric conditions"}]},"trialDetails":[{"nctId":"NCT02439125","phase":"PHASE2","title":"A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients","status":"UNKNOWN","sponsor":"Amarantus BioScience Holdings, Inc.","startDate":"2015-05","conditions":"Parkinson's Disease, Dyskinesia","enrollment":60},{"nctId":"NCT01266174","phase":"PHASE2","title":"Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults","status":"COMPLETED","sponsor":"Amarantus BioScience Holdings, Inc.","startDate":"2011-08","conditions":"Cognitive Impairment, Schizophrenia","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Eltoprazine HCl","genericName":"Eltoprazine HCl","companyName":"Amarantus BioScience Holdings, Inc.","companyId":"amarantus-bioscience-holdings-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}